Interactive Estimate
This educational tool gives a range-based estimate for people with Gleason score 9 (Grade Group 5) prostate cancer. It is not a diagnosis and not a substitute for your oncology team.
Educational model only. Real prognosis depends on pathology details, genomic testing, response to therapy, imaging findings, and clinician judgment.
What does Gleason score 9 mean?
Gleason score 9 (typically 4+5 or 5+4) belongs to Grade Group 5, the highest-grade category in prostate cancer. It reflects aggressive tumor biology and a higher risk of progression compared with lower scores.
That said, life expectancy is never based on Gleason score alone. A useful estimate must also consider:
- Age and overall health
- PSA at diagnosis
- T stage (local extent of tumor)
- Lymph node and metastatic status
- Treatment intensity and response
- Functional status (ECOG) and comorbid illness
How this calculator works
This page uses a simplified risk-index method to provide 5-year and 10-year overall survival ranges, plus a rough median survival range. It adjusts a baseline profile for Gleason 9 using your entries.
Why it reports ranges instead of one number
Prognosis in high-grade prostate cancer is uncertain and individualized. A range communicates uncertainty better than a single point estimate. If your estimated range appears broad, that is expected and clinically realistic.
How to interpret your result
- Do not use this tool to make treatment decisions by itself.
- Compare results under different treatment strategies to prepare better questions for your oncologist.
- Update inputs after major milestones (new imaging, treatment response, progression, or remission period).
- Bring your personalized estimate to clinic visits and discuss whether your actual case is better or worse than the model assumptions.
Factors that can improve outcomes in Gleason 9 disease
1) Early, coordinated specialist care
Multi-disciplinary care (urologic oncology, radiation oncology, medical oncology) often improves treatment sequencing and follow-up.
2) Appropriate combined therapy
For many patients with very high-risk localized disease, combinations such as radiation plus long-term androgen deprivation are commonly used. In selected cases, surgery-based pathways with adjuvant or salvage treatment may also be considered.
3) Monitoring and response-guided adjustment
PSA trends, modern imaging, and treatment tolerance all matter. Prognosis can change positively when disease responds strongly to therapy.
4) Managing general health
Cardiovascular health, diabetes control, exercise, nutrition, sleep, and mental health support can influence overall survival and quality of life.
Questions to ask your care team
- Is my case high-risk localized, node-positive, or metastatic?
- What is my intent of treatment: cure, long-term control, or symptom-focused?
- Should I receive local therapy, systemic therapy, or both?
- Would genomic testing or advanced imaging change my plan?
- How often should PSA and imaging be repeated?
- What side effects should I expect and how can we prevent them?
Limitations and disclaimer
This calculator is an educational estimate for informational use only. It is not a validated clinical prediction model and does not replace medical advice, diagnosis, or treatment planning. If you are making decisions about cancer therapy, please work directly with a qualified oncology team.